First DataBank's FIRSTLight Goes Live

First DataBankFirst DataBank's new online medicines reference tool, FIRSTLight, is now live and First DataBank is offering a free extended trial until the end of January 2011. FIRSTLight provides instant access to reliable medicines information, empowering clinicians and supporting safer, faster clinical decision making.

This is the first time First DataBank's trusted medicines information has been available stand alone and accessible at any point in the clinical workflow.

"We introduce FIRSTLight in direct response to requests from individual clinicians and Trusts for instant access to First DataBank's complete electronic medicines information," says Polly Shepperdson, Product Manager at First DataBank.

Several clinical system vendors have expressed early interest in partnering opportunities. Darren Nichols, Managing Director of First DataBank, comments: "Our current business partners are keen to add the immediate value and benefit of FIRSTLight to support their customers' medicines managements needs."

Specific features of FIRSTLight include:

  • How, when and when not to use a medication including ingredients, indications, doses, routes and administration advice
  • When to avoid using a medication, information about allergies and safety of use with other concurrent conditions, drugs and food
  • Tests, measures and observations required while using a medication including what should be done about any resulting changes, along with information about managing expected side effects and what to do in cases of over-dosage
  • Reproduction, pregnancy and breastfeeding advice including whether taking the medication can affect fertility, relevant recommendations for use of contraception and any risks associated with pregancy or breastfeeding while taking the medication.

FIRSTLight iPhone and iPad applications will also be available in early 2011.

To begin using FIRSTLight today, sign up for your free trial at www.firstdatabank.co.uk/firstlight

Related news articles:

About First DataBank
First DataBank is the UK's leading provider of drug knowledge bases and active clinical decision support. With over 30 years' experience of maintaining, developing and integrating drug knowledge bases across the entire healthcare spectrum, First DataBank has unrivalled expertise and knowledge in this specialist field. NHS Connecting for Health has chosen First DataBank to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. Through the effective integration of our products into clinical systems, we enable safer prescribing, dispensing and administration.

Our Multilex Drug Data File - the UK's most comprehensive and widely used drug knowledge base - is in daily use by thousands of healthcare professionals in the UK.

For further information visit www.firstdatabank.co.uk.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...